Literature DB >> 16225824

Rett syndrome: model of neurodevelopmental disorders.

Alan K Percy1, Jane B Lane.   

Abstract

Rett syndrome is a neurodevelopmental disorder that primarily affects girls, most of whom have mutations in the transcription regulatory gene MECP2. However, mutations in MECP2 also have been identified in normal carrier female individuals, female individuals with mild learning disabilities and features of Angelman syndrome, and male individuals with Klinefelter syndrome or Rett syndrome-like features, fatal neonatal encephalopathy, and familial X-linked mental retardation with or without motor abnormalities. Therefore, molecular testing should be considered for a wide spectrum of individuals. As such, Rett syndrome remains a clinical diagnosis. In this article, we also discuss three recent developments: (1) the recognition of significant gallbladder dysfunction, especially in those 20 years of age or younger; (2) a clinical trial of folate and betaine, which produced no objective improvement but did yield a subjective increase in attention and interaction; and (3) measurement of cerebrospinal fluid folate levels in a large cohort, which yielded normal values, indicating no need for supplementation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16225824     DOI: 10.1177/08830738050200090301

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  28 in total

1.  Modeling Rett syndrome with stem cells.

Authors:  Ryan M Walsh; Konrad Hochedlinger
Journal:  Cell       Date:  2010-11-12       Impact factor: 41.582

Review 2.  Transient receptor potential channels as novel effectors of brain-derived neurotrophic factor signaling: potential implications for Rett syndrome.

Authors:  Michelle D Amaral; Christopher A Chapleau; Lucas Pozzo-Miller
Journal:  Pharmacol Ther       Date:  2006-11-21       Impact factor: 12.310

3.  Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations.

Authors:  Christopher A Chapleau; Gaston D Calfa; Meredith C Lane; Asher J Albertson; Jennifer L Larimore; Shinichi Kudo; Dawna L Armstrong; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-05-12       Impact factor: 5.996

4.  EEA1 restores homeostatic synaptic plasticity in hippocampal neurons from Rett syndrome mice.

Authors:  Xin Xu; Lucas Pozzo-Miller
Journal:  J Physiol       Date:  2017-07-12       Impact factor: 5.182

Review 5.  Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives.

Authors:  Christopher A Chapleau; Jane Lane; Lucas Pozzo-Miller; Alan K Percy
Journal:  Curr Clin Pharmacol       Date:  2013-11

6.  Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities.

Authors:  J C Hodge; E Mitchell; V Pillalamarri; T L Toler; F Bartel; H M Kearney; Y S Zou; W H Tan; C Hanscom; S Kirmani; R R Hanson; S A Skinner; R C Rogers; D B Everman; E Boyd; C Tapp; S V Mullegama; D Keelean-Fuller; C M Powell; S H Elsea; C C Morton; J F Gusella; B DuPont; A Chaubey; A E Lin; M E Talkowski
Journal:  Mol Psychiatry       Date:  2013-04-16       Impact factor: 15.992

7.  Longevity in Rett syndrome: analysis of the North American Database.

Authors:  Russell S Kirby; Jane B Lane; Jerry Childers; Steve A Skinner; Fran Annese; Judy O Barrish; Daniel G Glaze; Patrick Macleod; Alan K Percy
Journal:  J Pediatr       Date:  2010-01       Impact factor: 4.406

8.  Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations.

Authors:  Jennifer L Larimore; Christopher A Chapleau; Shinichi Kudo; Anne Theibert; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-01-03       Impact factor: 5.996

Review 9.  BDNF deregulation in Rett syndrome.

Authors:  Wei Li; Lucas Pozzo-Miller
Journal:  Neuropharmacology       Date:  2013-04-15       Impact factor: 5.250

10.  Betaine enhances antidepressant-like, but blocks psychotomimetic effects of ketamine in mice.

Authors:  Jen-Cheng Lin; Mei-Yi Lee; Ming-Huan Chan; Yi-Chyan Chen; Hwei-Hsien Chen
Journal:  Psychopharmacology (Berl)       Date:  2016-06-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.